Pharmacia Trelstar LA Fourth LHRH Entrant In Prostate Cancer Arsenal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacia’s prostate cancer therapy Trelstar LA will enter the U.S. market as the fourth luteinizing hormone-releasing hormone (LHRH) analogue approved for treatment of the disease. The three-month, 11.5 mg formulation of triptorelin pamoate cleared FDA June 29 for the "palliative treatment of advanced prostate cancer."